CLINICAL_TRIALS
trial_result
· 2018-04-24
Clinical Trial Update: Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE [Phase 3]
Summary
Phase 3 trial evaluating DX-2930 for preventing acute angioedema attacks in patients with hereditary angioedema (HAE).
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Shire | Conditions: Hereditary Angioedema (HAE) | Phase 3 | Status: COMPLETED | Results posted: 2018-04-24